Published in JAMA on September 10, 2026, the phase 3 LAIS trial reports a notable result for a field with a long history of unsuccessful neuroprotection studies. Intravenous loberamisal improved 90-day functional outcome compared with placebo in adults treated within 48 hours of acute ischemic stroke. The effect deserves attention—but the evidence also deserves disciplined interpretation.
Plain-Language Summary
LAIS enrolled 998 adults with acute ischemic stroke at 32 hospitals in China. Participants were randomly assigned to receive intravenous loberamisal 40 mg or matching placebo once daily for 10 days, in addition to standard stroke care. At 90 days, 69.7% of participants receiving loberamisal achieved a modified Rankin Scale (mRS) score of 0–1, compared with 56.3% receiving placebo. That corresponds to an absolute difference of 13.28 percentage points and a relative risk of 1.24.
Serious adverse events and mortality were numerically similar between groups. However, several secondary functional outcomes did not show significant differences, patients treated with endovascular thrombectomy were excluded, and all participants were enrolled in China. A single positive phase 3 trial—especially with an unusually large effect in a historically difficult field—should be independently replicated before the result is generalized broadly.
What the Study Asked
Acute ischemic stroke can leave substantial disability even when reperfusion therapy is available. Loberamisal is being studied as a combined neuroprotective and neuroreparative agent, with proposed effects on excitotoxic signaling, inhibitory GABA pathways, neuroinflammation, and neural recovery.
The LAIS investigators asked whether adding intravenous loberamisal to standard care would improve functional outcomes in adults presenting within 48 hours of ischemic stroke onset.
Trial Design
- Design: Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial.
- Sites: 32 hospitals in China.
- Participants: Adults aged 18–80 years with acute ischemic stroke, baseline NIHSS 7–20, prestroke mRS ≤1, and presentation within 48 hours of symptom onset.
- Randomization: 1:1 using a centralized web-based system, stratified by study center and time from symptom onset.
- Intervention: Loberamisal 40 mg IV once daily for 10 days plus standard care.
- Control: Matching placebo IV once daily for 10 days plus standard care.
- Primary outcome: mRS score 0–1 at 90 days.
- Important eligibility point: Intravenous thrombolysis was permitted, but patients receiving endovascular thrombectomy were excluded.
The placebo was matched in appearance, packaging, and labeling. Participants, investigators, care providers, outcome assessors, and statisticians were blinded to allocation.
What LAIS Found
Among 997 participants included in the primary analysis, 350 of 502 participants in the loberamisal group (69.7%) achieved an mRS score of 0–1 at 90 days, compared with 279 of 495 in the placebo group (56.3%).
- Relative risk: 1.24 (95% CI, 1.12–1.36)
- Absolute risk difference: 13.28 percentage points (95% CI, 7.24–19.32)
A prespecified sliding-dichotomy analysis also favored loberamisal. But several conventional secondary measures were neutral, including early NIHSS improvement at day 10 and the proportion reaching a Barthel Index of at least 95 at day 90. Because secondary outcomes were not adjusted for multiplicity, they should also be interpreted as exploratory.
Safety
Overall adverse events occurred in 87.8% of participants receiving loberamisal and 88.7% receiving placebo. Serious adverse events occurred in 8.6% and 10.7%, respectively; all-cause mortality was 1.2% and 2.0%.
These data are reassuring within the trial, but they should not be interpreted as proof that uncommon harms are absent. Larger and more diverse confirmatory studies would provide a stronger estimate of safety.
Methodological Quality
Assessment: HIGH — rigorously randomized, double-blind, placebo-controlled phase 3 evidence, with important replication and external-validity caveats.
The core design strongly supports causal inference. Centralized randomization, matching placebo, broad blinding, prespecified outcomes, low loss to follow-up, multiple-imputation handling of missing primary outcomes, and independent statistical analyses all strengthen internal validity.
At the same time, the result should not be treated as definitive evidence for universal stroke practice. The treatment effect is unusually large relative to the history of neuroprotective trials, and external confirmation remains especially important.
Strengths
- Large phase 3 randomized sample for a neuroprotection study.
- Double-blind, placebo-controlled design with centralized allocation.
- Clinically meaningful 90-day functional endpoint.
- Very low final follow-up loss, with prespecified handling of missing data.
- Consistent primary-result sensitivity analyses.
- Independent academic statistical analysis alongside a separate regulatory analysis.
Limitations and Cautions
- Single-country population: All participants were enrolled in China, limiting certainty about generalizability to other health systems and patient populations.
- Thrombectomy excluded: The trial does not establish whether loberamisal adds benefit in patients receiving modern endovascular thrombectomy.
- Stroke-severity range: Very mild and very severe strokes were underrepresented.
- Secondary-outcome inconsistency: Several secondary measures did not differ significantly between groups, which tempers confidence in how broadly the primary result reflects neurological recovery.
- Implementation burden: Ten consecutive days of IV therapy may be difficult to reproduce in systems with shorter acute-stroke hospital stays.
- Mechanism remains uncertain: The prolonged regimen makes it difficult to determine whether any benefit arises from acute neuroprotection, reperfusion-phase effects, later neurorepair, or a combination.
- Replication is essential: Neuroprotection has a long history of promising preclinical and early clinical signals that failed to reproduce. Independent multinational confirmation would substantially strengthen confidence.
Funding and Conflicts of Interest
The study was supported by the National Natural Science Foundation of China and NeuroDawn Pharmaceutical Co., Ltd. The JAMA report states that the funders had no role in study design or conduct, data collection or management, analysis or interpretation, manuscript preparation or approval, or the decision to submit for publication. The authors reported no conflicts of interest.
Industry support does not invalidate a randomized trial, but it remains relevant context. In a single positive pivotal study, independent replication and access to robust confirmatory evidence are particularly valuable.
Soleil Insight
A striking phase 3 signal is a reason to replicate—not a reason to skip replication.
LAIS provides credible randomized evidence that loberamisal may improve 90-day functional recovery after acute ischemic stroke in the population studied. The next decisive question is whether this magnitude of benefit reproduces independently across different stroke systems, populations, reperfusion pathways, and treatment settings.
Original Publication
Li S, Feng B, He D, et al; LAIS Investigators. Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial. JAMA. Published online September 10, 2026. doi:10.1001/jama.2026.16557. ClinicalTrials.gov: NCT06517173.
Read the original JAMA publication
Featured image: National Heart, Lung, and Blood Institute (NIH), public-domain illustration of ischemic stroke. The image is illustrative and is not from a LAIS participant.
Soleil Research™
Advancing Science. Empowering Humanity.